Checkpoint Therapeutics Inc (CKPT)
2.12
+0.07
(+3.41%)
USD |
NASDAQ |
Jun 14, 16:00
2.07
-0.05
(-2.36%)
After-Hours: 20:00
Checkpoint Therapeutics Research and Development Expense (Annual): 43.57M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 43.57M |
| December 31, 2022 | 49.82M |
| December 31, 2021 | 48.45M |
| December 31, 2020 | 16.35M |
| December 31, 2019 | 19.32M |
| Date | Value |
|---|---|
| December 31, 2018 | 33.65M |
| December 31, 2017 | 19.08M |
| December 31, 2016 | 20.27M |
| December 31, 2015 | 11.32M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
16.35M
Minimum
2020
49.82M
Maximum
2022
35.50M
Average
43.57M
Median
2023
Research and Development Expense (Annual) Benchmarks
| QuidelOrtho Corp | 246.80M |
| Fortress Biotech Inc | 106.07M |
| Anavex Life Sciences Corp | 43.72M |
| Ocugen Inc | 39.57M |
| NovaBay Pharmaceuticals Inc | 0.068M |